OBJECTIVES: We investigated the relationship between BRCA1 protein expression by immunohistochemistry (IHC) and clinical outcome following platinum and platinum/taxane chemotherapy in sporadic epithelial ovarian cancer (EOC). METHODS: BRCA1 IHC was performed on a cohort of 292 ovarian tumours from two UK oncology centres. BRCA1 protein expression levels were correlated with overall survival (OS), progression free survival (PFS) and clinical response to chemotherapy by multivariate analysis. RESULTS: EOC patients with absent/low BRCA1 protein expression (41%) had a better chance of clinical response following chemotherapy as compared to patients with high BRCA1 expression (odds ratio 2.47: 95%CI 1.10-5.55, p=0.029). Patients with absent/low BRCA1 had a higher probability of clinical response following single agent platinum compared to high BRCA1 expressing patients (68.5% vs. 46.8%), while addition of a taxane increased response rates independent of BRCA1. Overall, patients with absent/low BRCA1 had a better clinical outcome compared to patients with high BRCA1 protein expression in terms of both OS (HR=0.65: 95%CI 0.48-0.88, p=0.006) and PFS (HR=0.74, 95%CI 0.55-0.98, p=0.040). CONCLUSIONS: We confirm that absent/low BRCA1 protein expression is a favourable prognostic marker. However, we also provide the first evidence that absent/low BRCA1 protein expression in sporadic EOC patients predicts for an improved clinical response to chemotherapy.
OBJECTIVES: We investigated the relationship between BRCA1 protein expression by immunohistochemistry (IHC) and clinical outcome following platinum and platinum/taxane chemotherapy in sporadic epithelial ovarian cancer (EOC). METHODS:BRCA1 IHC was performed on a cohort of 292 ovarian tumours from two UK oncology centres. BRCA1 protein expression levels were correlated with overall survival (OS), progression free survival (PFS) and clinical response to chemotherapy by multivariate analysis. RESULTS: EOC patients with absent/low BRCA1 protein expression (41%) had a better chance of clinical response following chemotherapy as compared to patients with high BRCA1 expression (odds ratio 2.47: 95%CI 1.10-5.55, p=0.029). Patients with absent/low BRCA1 had a higher probability of clinical response following single agent platinum compared to high BRCA1 expressing patients (68.5% vs. 46.8%), while addition of a taxane increased response rates independent of BRCA1. Overall, patients with absent/low BRCA1 had a better clinical outcome compared to patients with high BRCA1 protein expression in terms of both OS (HR=0.65: 95%CI 0.48-0.88, p=0.006) and PFS (HR=0.74, 95%CI 0.55-0.98, p=0.040). CONCLUSIONS: We confirm that absent/low BRCA1 protein expression is a favourable prognostic marker. However, we also provide the first evidence that absent/low BRCA1 protein expression in sporadic EOC patients predicts for an improved clinical response to chemotherapy.
Authors: Karuna Garg; Douglas A Levine; Narciso Olvera; Fanny Dao; Maria Bisogna; Angeles Alvarez Secord; Andrew Berchuck; Ethan Cerami; Nikolaus Schultz; Robert A Soslow Journal: Am J Surg Pathol Date: 2013-01 Impact factor: 6.394
Authors: J Hilton; J Weberpals; I Lorimer; S Amin; S Islam; L Pelletier; M Daneshmand; J Hanson; M Nabavi; D Parolin; R Mallick; S Verma Journal: Oncol Lett Date: 2012-04-26 Impact factor: 2.967
Authors: Raushan T Kurmasheva; Dias Kurmashev; C Patrick Reynolds; Min Kang; Jianwrong Wu; Peter J Houghton; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2017-09-17 Impact factor: 3.167
Authors: S Pontikakis; C Papadaki; M Tzardi; M Trypaki; M Sfakianaki; F Koinis; E Lagoudaki; L Giannikaki; A Kalykaki; E Kontopodis; Z Saridaki; N Malamos; V Georgoulias; J Souglakos Journal: Pharmacogenomics J Date: 2016-10-25 Impact factor: 3.550
Authors: J L Meisel; D M Hyman; K Garg; Q Zhou; F Dao; M Bisogna; J Gao; N D Schultz; R N Grisham; M Phillips; A Iasonos; N D Kauff; D A Levine; R A Soslow; D R Spriggs Journal: Ann Oncol Date: 2014-10-03 Impact factor: 32.976